Moderna and Pfizer Vaccines: A Comparative Overview
Written on
Chapter 1: Introduction to Covid-19 Vaccines
The initial Covid-19 vaccines from Moderna and Pfizer have provided promising updates in the fight against the pandemic. Recent late-stage trial results from both companies have set a high standard for upcoming competitors like AstraZeneca, which are anticipated to release their own significant findings soon. This data instills greater confidence that additional vaccines will prove effective, paving the way for better control over the coronavirus. Here’s a closer look at these two vaccines and how they measure up against each other.
Section 1.1: Effectiveness of the Vaccines
Moderna announced that its vaccine demonstrated a 94.5% efficacy rate in early analyses, which is impressive compared to the over 90% effectiveness reported by Pfizer and its partner, BioNTech, just a week earlier. Both vaccines exhibited only short-lived side effects, with no major safety issues reported. Notably, none of the participants who received the Moderna vaccine experienced serious cases of Covid during the trial. Earlier this year, U.S. health authorities stipulated that any vaccine should achieve a minimum effectiveness of 50%.
Section 1.2: Common Technologies Used
Both Moderna and Pfizer utilize a novel technology known as messenger RNA (mRNA), which has never been previously used in an approved vaccine. This innovative method enables the body’s cells to act as factories that produce vaccine components. By instructing cells to generate copies of the coronavirus's spike protein, the vaccines effectively stimulate the immune system to create protective antibodies.
Subsection 1.2.1: Financial Backing
Moderna received substantial funding amounting to $955 million from the U.S. government's Operation Warp Speed initiative. In contrast, Pfizer did not accept federal funds for its vaccine development, although BioNTech secured up to 375 million euros (approximately $444 million) in support from the German government. Nonetheless, Pfizer has entered into a supply agreement with the U.S. valued at nearly $2 billion, while the U.S. has committed to purchasing up to $1.53 billion worth of Moderna’s vaccine.
Chapter 2: Distribution and Storage Challenges
This video titled "Moderna v Pfizer, deaths - YouTube" discusses critical insights regarding the vaccines' safety profiles, including reported adverse events and mortality data.
The distribution and storage of these vaccines present additional challenges that must be addressed as vaccination efforts ramp up. Pfizer's vaccine requires ultra-cold storage until shortly before administration, although it can be stored at refrigerator temperatures for up to five days. Moderna's recent data indicates that its vaccine remains stable at refrigerator temperatures for 30 days—much longer than the previously estimated seven days—and can be stored in freezers for extended periods without the need for specialized facilities.
Section 2.1: Initial Distribution Plans
Global vaccine demand is projected to outstrip supply initially, despite preparations to boost production. Moderna has already secured contracts to deliver 100 million doses to the U.S. and 80 million to the European Union, among other agreements. The U.K. has begun negotiations with Moderna, though it may not receive doses until spring at the earliest. Pfizer and BioNTech are also working on agreements for hundreds of millions of shots.
Section 2.2: Timeline for Emergency Use Authorization
Both vaccine candidates are expected to pursue emergency-use authorization from the U.S. Food and Drug Administration (FDA) if further evaluations confirm their safety. Moderna indicated that it might seek regulatory approval in the near future, while Pfizer anticipates acquiring two months' worth of safety data by the third week of November. If everything progresses smoothly, Pfizer could apply for U.S. authorization this month.
Chapter 3: Remaining Questions and Challenges
The video titled "Here's the key differences between Moderna and Pfizer vaccines - YouTube" explores the distinctions between the two vaccines, including their mechanisms and efficacy profiles.
Despite the encouraging results, several questions remain. It's uncertain how long the immunity provided by these vaccines will last and how many individuals may decline vaccination once it becomes available. Health advocates express concern that rising skepticism about Covid-19 vaccines could hinder the rollout. Additionally, scaling up production and ensuring effective distribution of vaccine doses remain significant obstacles.
— With contributions from Naomi Kresge.